Dimensional Fund Advisors LP Kezar Life Sciences, Inc. Transaction History

Dimensional Fund Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$2.31 - $3.06 $141,739 - $187,758	-61,359 Reduced 73.25%	22,403 $54,000
Q1 2023 May 12, 2023	SELL	$3.13 - $7.31 $1.13 Million - $2.63 Million	-359,673 Reduced 81.11%	83,762 $262,000
Q4 2022 Feb 09, 2023	SELL	$6.39 - $8.8 $1.69 Million - $2.33 Million	-264,331 Reduced 37.35%	443,435 $3.12 Million
Q3 2022 Nov 10, 2022	BUY	$7.99 - $10.75 $2.59 Million - $3.48 Million	323,726 Added 84.29%	707,766 $6.09 Million
Q2 2022 Aug 12, 2022	BUY	$4.58 - $17.13 $485,992 - $1.82 Million	106,112 Added 38.18%	384,040 $3.18 Million
Q1 2022 May 13, 2022	BUY	$12.3 - $18.33 $26,199 - $39,042	2,130 Added 0.77%	277,928 $4.62 Million
Q4 2021 Feb 09, 2022	BUY	$7.44 - $16.72 $795,566 - $1.79 Million	106,931 Added 63.32%	275,798 $4.61 Million
Q3 2021 Nov 12, 2021	BUY	$4.85 - $9.73 $655,133 - $1.31 Million	135,079 Added 399.78%	168,867 $1.46 Million
Q2 2021 Aug 12, 2021	BUY	$4.93 - $6.46 $166,574 - $218,270	33,788 New	33,788 $183,000

39.6M

3.2K

700

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $36.9M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.